Skip to main content

Advertisement

Table 4 Common (≥ 20%) JS001 treatment-related adverse events from all subjects (n = 36)

From: Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Treatment-related AE N (%) Grade 1 2 3 4
Hyperglycemia 21 (58.33%) 19 1 1 0
Proteinuria 18 (50.00%) 14 3 1 0
Rash 16 (44.44%) 16 0 0 0
Thyroid stimulating hormone increased 16 (44.44%) 15 1 3 0
Lipase increased 14 (38.89%) 9 1 4 0
Fever 14 (38.89%) 13 1 0 0
Tri-iodothyronine free decreased 13 (36.11%) 12 1 0 0
Sinus tachycardia 12 (33.33%) 12 0 0 0
Anemia 12 (33.33%) 6 3 3 0
Leukocyturia 11 (30.56%) 11 0 0 0
Pruritus 9 (25.00%) 9 0 0 0
Leukopenia 9 (25.00%) 6 3 0 0
Amylase increased 9 (25.00%) 7 1 1 0
Thyroid hormone increases 9 (25.00%) 9 0 0 0
DBIL 9 (25.00%) 4 3 2 0
Hematuria 9 (25.00%) 9 0 0 0
AST increased 9 (25.00%) 9 0 0 0
Thyroid stimulating hormone decreased increased 9 (25.00%) 9 0 0 0
Hypochloremia 9 (25.00%) 9 0 0 0
White blood cell count increased 8 (22.22%) 8 0 0 0
ALT increased AAL 8 (22.22%) 7 0 1 0
TBIL increased 8 (22.22%) 6 2 0 0
Appetite decreased 8 (22.22%) 8 0 0 0
Fatigue 8 (22.22%) 7 1 0 0
  1. By the safety data cutoff date of July 31, 2018, common TRAE total occurrence number (rate) and number in each grade were listed